ATE552272T1 - Myostatin-isoform - Google Patents
Myostatin-isoformInfo
- Publication number
- ATE552272T1 ATE552272T1 AT05790714T AT05790714T ATE552272T1 AT E552272 T1 ATE552272 T1 AT E552272T1 AT 05790714 T AT05790714 T AT 05790714T AT 05790714 T AT05790714 T AT 05790714T AT E552272 T1 ATE552272 T1 AT E552272T1
- Authority
- AT
- Austria
- Prior art keywords
- present
- sequences
- myostatin
- muscle
- splice variants
- Prior art date
Links
- 102000004472 Myostatin Human genes 0.000 title abstract 2
- 108010056852 Myostatin Proteins 0.000 title abstract 2
- 102000001708 Protein Isoforms Human genes 0.000 title 1
- 108010029485 Protein Isoforms Proteins 0.000 title 1
- 210000003205 muscle Anatomy 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 2
- 230000037257 muscle growth Effects 0.000 abstract 2
- 108091035707 Consensus sequence Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 238000009394 selective breeding Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NZ53569604A NZ535696A (en) | 2004-09-30 | 2004-09-30 | Myostatin splice variants ( MSV ) |
| NZ53839605 | 2005-02-22 | ||
| PCT/NZ2005/000250 WO2006036074A1 (en) | 2004-09-30 | 2005-09-30 | Myostatin isoform |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE552272T1 true ATE552272T1 (de) | 2012-04-15 |
Family
ID=36119161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05790714T ATE552272T1 (de) | 2004-09-30 | 2005-09-30 | Myostatin-isoform |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080118487A1 (enExample) |
| EP (1) | EP1799709B1 (enExample) |
| JP (1) | JP5335239B2 (enExample) |
| AT (1) | ATE552272T1 (enExample) |
| CA (1) | CA2582940A1 (enExample) |
| WO (1) | WO2006036074A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100898149B1 (ko) | 2007-04-05 | 2009-05-19 | 주식회사 에스엔피 제네틱스 | 소의 근내지방도와 연관되어 있는 티틴-캡 다형성 |
| EP2981822B1 (en) | 2013-05-06 | 2020-09-02 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| WO2019195679A1 (en) * | 2018-04-06 | 2019-10-10 | Intrexon Corporation | Tilapia with enhanced growth characteristics |
| US12202869B2 (en) | 2019-03-01 | 2025-01-21 | Knc Laboratories Co., Ltd. | Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof |
| CN115201474A (zh) * | 2022-08-12 | 2022-10-18 | 万华普曼生物工程有限公司 | 一种新型冠状病毒抗体的快速检测试剂盒及其制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4487325A (en) | 1982-07-06 | 1984-12-11 | Owens-Illinois, Inc. | Crown closures and containers |
| US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
| US5874409A (en) * | 1995-06-07 | 1999-02-23 | La Jolla Pharmaceutical Company | APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies |
| WO1998033887A1 (en) | 1997-02-05 | 1998-08-06 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US6656475B1 (en) * | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| US6369201B1 (en) | 1998-02-19 | 2002-04-09 | Metamorphix International, Inc. | Myostatin multimers |
| JP2003506325A (ja) | 1999-07-20 | 2003-02-18 | ファーメクサ エイ／エス | Ｇｄｆ−８活性のダウン−レギュレート方法 |
| AU782925B2 (en) * | 2000-01-18 | 2005-09-08 | Orico Limited | Myostatin and mimetics thereof |
| CN1650012A (zh) | 2002-07-24 | 2005-08-03 | 英特塞尔股份公司 | 来自致病病毒的备选阅读框所编码的抗原 |
| DE60331778D1 (de) * | 2002-09-16 | 2010-04-29 | Univ Johns Hopkins | Metalloproteaseaktivierung von myostatin und verfahren zur modulation der myostatinaktivität |
| NZ529860A (en) * | 2003-11-28 | 2006-10-27 | Ovita Ltd | Muscle growth regulator mighty and use in promoting muscle mass and treating muscle wasting diseases |
| WO2005066204A2 (en) * | 2003-12-31 | 2005-07-21 | Schering-Plough Ltd. | Neutralizing epitope-based growth enhancing vaccine |
| NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
| US20070190056A1 (en) | 2006-02-07 | 2007-08-16 | Ravi Kambadur | Muscle regeneration compositions and uses therefor |
| JP2009545313A (ja) * | 2006-08-03 | 2009-12-24 | オリコ・リミテッド | ミオスタチンアンタゴニスト |
-
2005
- 2005-09-30 JP JP2007534532A patent/JP5335239B2/ja not_active Expired - Fee Related
- 2005-09-30 EP EP05790714A patent/EP1799709B1/en not_active Expired - Lifetime
- 2005-09-30 US US11/576,449 patent/US20080118487A1/en not_active Abandoned
- 2005-09-30 CA CA002582940A patent/CA2582940A1/en not_active Abandoned
- 2005-09-30 WO PCT/NZ2005/000250 patent/WO2006036074A1/en not_active Ceased
- 2005-09-30 AT AT05790714T patent/ATE552272T1/de active
-
2011
- 2011-04-12 US US13/085,263 patent/US8455448B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1799709A1 (en) | 2007-06-27 |
| US20080118487A1 (en) | 2008-05-22 |
| US8455448B2 (en) | 2013-06-04 |
| JP5335239B2 (ja) | 2013-11-06 |
| JP2008514227A (ja) | 2008-05-08 |
| CA2582940A1 (en) | 2006-04-06 |
| US20110258712A1 (en) | 2011-10-20 |
| WO2006036074A1 (en) | 2006-04-06 |
| EP1799709B1 (en) | 2012-04-04 |
| EP1799709A4 (en) | 2008-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124332T1 (el) | Πεγκυλιωμενες ενωσεις ανασυνδυασμενης ανθρωπινης αυξητικης ορμονης | |
| MX2007007602A (es) | Agonistas del peptido 1 similar al glucagon, composiciones, metodos y usos. | |
| SG151315A1 (en) | Human glp-1 mimetibodies, compositions, methods and uses | |
| NO20111324A1 (no) | Rekombinant MVA-virus | |
| MA28418B1 (fr) | Anticorps liant un recepteur de l'interleucine 4 | |
| EA201000865A1 (ru) | Комбинация ингибиторов протеинтирозинфосфатазы и гормона роста человека, предназначенная для лечения атрофии мышц и родственных нарушений | |
| IS7770A (is) | Hlutleysandi mótefni gegn GDF-8 og notkun theirra | |
| EA200970131A1 (ru) | Миметические антитела для glp-1 человека, композиции, способы и применения | |
| ATE495739T1 (de) | Pharmazeutische zusammensetzungen und verfahren zur verwendung von levodopa und carbidopa | |
| EA200900345A1 (ru) | Замещенные ациланилиды и способы их применения | |
| EA200601107A1 (ru) | Композиции, получаемые из морских растений, для обеспечения питания для старческой и поврежденной окружающей средой кожи | |
| DK1715887T3 (da) | N-terminalt monopegyleret humant væksthormonkonjugater, fremgangsmåde til deres fremstilling og anvendelsen deraf | |
| ATE499105T1 (de) | Behandlung oder vorbeugung von haut- oder gewebezuständen bei tieren unter verwendung von boryloxypyridylmethanonen | |
| LU93259I2 (fr) | LETIFEND (Protein Q) | |
| EP1018976A4 (en) | Head-only animal exposure chambers | |
| DE59510466D1 (de) | Lebendvakzine zur behandlung von tumorerkrankungen | |
| ATE225803T1 (de) | Peptid zur verringerung des triglyzeridspiegels des blutes und inhibitor für den anstieg des triglyzeridspiegels des blutes, der das peptid als aktiven bestandteil enthält | |
| DK1599215T3 (da) | Anvendelse af tryptophanrige peptider fra mælkeproteinhydrolysat til behandling af overvægt og fedme | |
| ATE552272T1 (de) | Myostatin-isoform | |
| ATE285794T1 (de) | Die verwendung von retinoid antagonisten oder agonisten für die behandlung von gelenk-und knochenpathologien | |
| DE602005013788D1 (de) | ckrox-Peptide und ihre Analoge zur Behandlung von Hautalterung | |
| DE60324784D1 (de) | Behandlung zur reduzierung der zunahme des körpergewichts | |
| NO20023709D0 (no) | Transgen dyremodell for fedmeuttrykkende FoxC2 | |
| MX2009006670A (es) | Composicion farmaceutica que usa el aliskiren y el avosentan. | |
| NO20075272L (no) | Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser |